Maxim D. Hammer, MD

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.

Maxim D. Hammer, MD
Department of Neurology, The Cleveland Clinic

Derk W. Krieger, MD, PhD
Section of Stroke and Neurologic Intensive Care, Department of Neurology, The Cleveland Clinic; Co-principal investigator, Cooling for Acute Ischemic Brain Damage (COOL AID) study

Address: Derk W. Krieger, MD, PhD, Department of Neurology, S91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Krieger has indicated that he has received grant or research support from Radiant Medical Inc, is a consultant for Medcool, Inc, and is on the speakers’ bureaus of Sanofi-Synthelabo and the Bristol-Myers Squibb Company.

This paper discusses treatment that is not approved by the US Food and Drug Administration for the use under discussion.